IPN, Delhi, India. Open 10-6pm

+91 9891296838 / 9811747774

mosunetuzumab injection

mosunetuzumab-axgb injection,
For intravenous use Initial U.S. Approval: 2022

As specified in the prescribing information, mosunetuzumab-axgb injection is indicated for the treatment of Lymphoma disease. As per highlights Of prescribing information mosunetuzumab-axgb injection is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Facts about mosunetuzumab injection

Disease Indications: Lymphoma
Dosage Forms And Strengths:
• 1 mg/mL solution in a single-dose vial.
• 30 mg/30 mL (1 mg/mL) solution in a single-dose vial.
Manufacturer: Genentech, Inc
Usage: Intravenous
Medicine Approved By: European Medical Agency (EMA), Food and Drug Administration (FDA)
Lunsumio (mosunetuzumab-axgb) was approved by the EMA in June 20223 and the FDA in December 2022

Extra Information:

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “mosunetuzumab injection” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

Contact Info

Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.

M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398



Query For mosunetuzumab injection

Approved accessible "mosunetuzumab-axgb injection"

Mosunetuzumab, is a monoclonal antibody used for the treatment of follicular lymphoma. It bispecifically binds CD20 and CD3 to engage T-cells. It was developed by Genentech. Mosunetuzumab was approved for medical use in the European Union in June 2022, and in the United States in December 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. Mosunetuzumab is indicated for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

How can 1 go about obtaining mosunetuzumab injection?

If mosunetuzumab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Indian Pharma Network (IPN), New Delhi. India

Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa

Indian Pharma Network
60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016

Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398